NCT07413354 2026-02-17
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
Tongji Hospital
Phase 2 Recruiting
Clinical Trials
28 trialsNCT05532319 2025-12-30
FRONT-1
Guangxi Medical University
Phase 2 Completed
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07243691 2025-11-24
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
Sir Run Run Shaw Hospital
Phase NA Recruiting
NCT05622071 2025-11-17
HESTIA
UNICANCER
Phase 2 Completed
NCT07077369 2025-07-22
WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy
West China Hospital
Phase 1 Not yet recruiting
NCT07078305 2025-07-22
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07047586 2025-07-03
LEAF-01
Fudan University
Phase 2 Recruiting
NCT06420440 2025-05-01
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Tongji Hospital
Phase 2 Recruiting
NCT05920863 2025-02-11
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT06333561 2025-02-06
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Sun Yat-sen University
Recruiting
NCT04615143 2025-01-09
TALENT
Sun Yat-sen University
Phase 2 Recruiting
NCT06232759 2024-06-10
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 2 Completed
NCT06253598 2024-03-07
Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma
The First Affiliated Hospital of Bengbu Medical University
Phase 2 Not yet recruiting
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT06210334 2024-02-20
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
NCT05842317 2024-02-09
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT06233981 2024-01-31
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05533892 2023-12-19
CCGLC-007
Tongji Hospital
Phase 1 Unknown
NCT04652440 2023-04-19
Ablation Combined With PD-1 in HCC: Phase II Study
Sun Yat-sen University
Phase 1/2 Unknown
NCT04663035 2023-03-22
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
Sun Yat-sen University
Phase 2 Unknown
NCT05675462 2023-03-06
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
Fudan University
Phase 1 Unknown
NCT05339581 2022-04-27
iPLENTY-pvtt
RenJi Hospital
Phase NA Unknown
NCT05277675 2022-03-14
RANT
Southwest Hospital, China
Phase NA Unknown
NCT04981665 2022-01-05
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Zhejiang University
Phase 2 Unknown
NCT04996446 2021-08-09
ALPPS Combined With Tislelizumab in Liver Malignancy
Fudan University
Phase 2 Unknown
NCT04996459 2021-08-09
Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma
Fudan University
Unknown
NCT04652492 2020-12-03
Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma
Zhongda Hospital
Phase 2 Unknown